Retraction: Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27Kip1 upregulation (PLoS ONE (2010) 5:7 (e11668) DOI: 10.1371/journal.pone.0011668);Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27Kip1 upregulation

PLoS ONE

Volumn 5, Issue 7, 2010, Pages 1-12

  Gopinath, Sreelatha ^a   Malla, Rama Rao ^a   Gondi, Christopher S ^a   Alapati, Kiranmai ^a   Fassett, Daniel ^a   Klopfenstein, Jeffrey D ^a   Dinh, Dzung H ^a   Gujrati, Meena ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BROXURIDINE; CATHEPSIN B; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; LUCIFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; MORPHOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PLASMID; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; CELL CYCLE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CATHEPSIN B; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; CYCLIN D1; CYCLIN D2; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; GLIOMA; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MORPHOLINES; PROMOTER REGIONS, GENETIC; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 77955375925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0228690     Document Type: Erratum

References (71)

1. Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109: 93-108.
2. Gondi CS, Kandhukuri N, Kondraganti S, Gujrati M, Olivero WC, et al. (2006) RNA interference-mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells. Mol Cancer Ther 5: 3197-3208.
3. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, et al. (2004) RNAimediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23: 8486-8496.
4. Mohan PM, Lakka SS, Mohanam S, Kin Y, Sawaya R, et al. (1999) Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells. Clin Exp Metastasis 17: 617-621.
5. Morgan DO (1995) Principles of CDK regulation. Nature 374: 131-134.
6. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512.
7. Belletti B, Nicoloso MS, Schiappacassi M, Chimienti E, Berton S, et al. (2005) p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs. Curr Med Chem 12: 1589-1605.
8. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231.
9. Philipp-Staheli J, Payne SR, Kemp CJ (2001) p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264: 148-168.
10. Favrot M, Coll JL, Louis N, Negoescu A (1998) Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Ther 5: 728-739.
11. Bloom J, Pagano M (2003) Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 13: 41-47.
12. Alkarain A, Jordan R, Slingerland J (2004) p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 9: 67-80.
13. Lawlor MA, Alessi DR (2001) PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903-2910.
14. Di CA, Pandolfi PP (2000) The multiple roles of PTEN in tumor suppression. Cell 100: 387-390.
15. Testa JR, Bellacosa A (2001) AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985.
16. Brownawell AM, Kops GJ, Macara IG, Burgering BM (2001) Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol Cell Biol 21: 3534-3546.
17. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425.
18. Zhao X, Gan L, Pan H, Kan D, Majeski M, et al. (2004) Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. Biochem J 378: 839-849.
19. Clark KL, Halay ED, Lai E, Burley SK (1993) Co-crystal structure of the HNF- 3/fork head DNA-recognition motif resembles histone H5. Nature 364: 412-420.
20. Furuyama T, Nakazawa T, Nakano I, Mori N (2000) Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J 349: 629-634.
21. Kops GJ, Burgering BM (2000) Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J Anat 197 Pt 4: 571-4.: 571-574.
22. Lau CJ, Koty Z, Nalbantoglu J (2009) Differential response of glioma cells to FOXO1-directed therapy. Cancer Res 69: 5433-5440.
23. Shi J, Zhang L, Shen A, Zhang J, Wang Y, et al. (2009) Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27(kip1). J Neurooncol.
24. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3: 489-501.
25. Besson A, Dowdy SF, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169.
26. Harbour JW, Luo RX, Dei SA, Postigo AA, Dean DC (1999) Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869.
27. Hatakeyama M, Brill JA, Fink GR, Weinberg RA (1994) Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev 8: 1759-1771.
28. Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, et al. (1994) Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54: 6027-6031.
29. Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, et al. (1995) Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 13: 49-56.
30. Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, et al. (1994) Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 54: 5016-5020.
31. Obermajer N, Jevnikar Z, Doljak B, Kos J (2008) Role of cysteine cathepsins in matrix degradation and cell signalling. Connect Tissue Res 49: 193-196.
32. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF (2005) Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 118: 1493-1503.
33. Gladson CL, Pijuan-Thompson V, Olman MA, Gillespie GY, Yacoub IZ (1995) Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol 146: 1150-1160.
34. Mohanam S, Gladson CL, Rao CN, Rao JS (1999) Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors. Front Biosci 4: D178-D187.
35. Mohanam S, Go Y, Sawaya R, Venkaiah B, Mohan PM, et al. (1999) Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo. Int J Oncol 14: 169-174.
36. Yamamoto M, Sawaya R, Mohanam S, Rao VH, Bruner JM, et al. (1994) Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. J Neurooncol 22: 139-151.
37. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, et al. (2000) Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 14: 2589-2600.
38. Moles A, Tarrats N, Fernandez-Checa JC, Mari M (2009) Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 49: 1297-1307.
39. Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, et al. (2008) Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 27: 4191-4199.
40. Chu IM, Hengst L, Slingerland JM (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267.
41. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, et al. (2002) A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J 21: 3390-3401.
42. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, et al. (2002) PKB/ Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160.
43. Rodriguez-Ubreva FJ, Cariaga-Martinez AE, Cortes MA, Romero-De PM, Ropero S, et al. (2010) Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. Oncogene 29: 345-355.
44. Xu X, Nakano T, Wick S, Dubay M, Brizuela L (1999) Mechanism of Cdk2/ Cyclin E inhibition by p27 and p27 phosphorylation. Biochemistry 38: 8713-8722.
45. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR (1991) The E2F transcription factor is a cellular target for the RB protein. Cell 65: 1053-1061.
46. Dyson N (1998) The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262.
47. Lin BT, Gruenwald S, Morla AO, Lee WH, Wang JY (1991) Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J 10: 857-864.
48. Zarkowska T, Mittnacht S (1997) Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 272: 12738-12746.
49. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
50. Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-267.
51. Cancer Genome Atlas Research Network collaborators (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
52. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
53. Medema RH, Kops GJ, Bos JL, Burgering BM (2000) AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787.
54. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, et al. (2002) The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168: 5024-5031.
55. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
56. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, et al. (2000) Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20: 8969-8982.
57. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, et al. (2005) Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 280: 33558-33565.
58. Sue YM, Chung CP, Lin H, Chou Y, Jen CY, et al. (2009) PPARdelta-mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells. Am J Physiol Cell Physiol 297: C321-C329.
59. Wei Q, Miskimins WK, Miskimins R (2003) The Sp1 family of transcription factors is involved in p27(Kip1)-mediated activation of myelin basic protein gene expression. Mol Cell Biol 23: 4035-4045.
60. Li CJ, Chang JK, Chou CH, Wang GJ, Ho ML (2010) The PI3K/Akt/ FOXO3a/p27Kip1 signaling contributes to anti-inflammatory drug-suppressed proliferation of human osteoblasts. Biochem Pharmacol 79: 926-937.
61. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, et al. (2003) Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 101: 1439-1445.
62. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, et al. (2007) Intraperitoneal injection of an hpRNA-expressing plasmid targeting uPAR and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 13: 4051-4060.
63. Lakka SS, Gondi CS, Yanamandra N, Dinh DH, Olivero WC, et al. (2003) Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 63: 2454-2461.
64. Tralhao JG, Schaefer L, Micegova M, Evaristo C, Schonherr E, et al. (2003) In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 17: 464-466.
65. Yu W, Kim J, Ossowski L (1997) Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 137: 767-777.
66. D'Alessio S, Margheri F, Pucci M, Del Rosso A, Monia BP, et al. (2004) Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer 110: 125-133.
67. Van BG, Gray MJ, Dallas NA, Xia L, Lim SJ, et al. (2009) Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 115: 3360-3368.
68. Mazzieri R, Furlan F, D'Alessio S, Zonari E, Talotta F, et al. (2007) A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts. Oncogene 26: 725-732.
69. Lund AH, Turner G, Trubetskoy A, Verhoeven E, Wientjens E, et al. (2002) Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 32: 160-165.
70. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, et al. (2004) Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23: 4681-4689.
71. Gondi CS, Lakka SS, Dinh D, Olivero W, Gujrati M, et al. (2004) Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biology 1: 165-176.